Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016', provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis)
- The report reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Burkholderia pseudomallei Infections (Melioidosis) therapeutics and enlists all their major and minor projects
- The report assesses Burkholderia pseudomallei Infections (Melioidosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis)


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Burkholderia pseudomallei Infections (Melioidosis) Overview 7
Therapeutics Development 8
Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Overview 8
Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis 9
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Development by Companies 10
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Investigation by Universities/Institutes 11
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Products Glance 12
Early Stage Products 12
Burkholderia pseudomallei Infections (Melioidosis) - Products under Development by Companies 13
Burkholderia pseudomallei Infections (Melioidosis) - Products under Investigation by Universities/Institutes 14
Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development 15
Bavarian Nordic A/S 15
Emergent BioSolutions Inc. 16
Grifols, S.A. 17
Soligenix, Inc. 18
Syntiron LLC 19
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ARD-3100 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ARD-3150 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Burkholderia pseudomallei vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Burkholderia vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dusquetide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
EV-035 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GC-072 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
melioidosis vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SGX-101 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SGX-943 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Burkholderia pseudomallei Infections (Melioidosis) - Recent Pipeline Updates 46
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects 56
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products 57
Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones 58
Featured News & Press Releases 58
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 58
Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072 58
Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 59
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H1 2016 8
Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H1 2016 15
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc., H1 2016 16
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols, S.A., H1 2016 17
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix, Inc., H1 2016 18
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Burkholderia pseudomallei Infections (Melioidosis) Therapeutics - Recent Pipeline Updates, H1 2016 46
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H1 2016 56
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H1 2016 57